Fibrous Dysplasia and Fibroblast Growth Factor-23 Regulation

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Osteoporosis Reports

• Publication date

  2013-03-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11914-013-0144-5PMID 23532406PMCID PMC3669677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23–related hypophosphatemia, dental anomalies, and ectopic calcification

  2013cited by this paper
• Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.

  2013cited by this paper
• Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

  2013cited by this paper
• Hexa‐D‐arginine treatment increases 7B2•PC2 activity in hyp‐mouse osteoblasts and rescues the HYP phenotype

  2013cited by this paper
• Mechanism of FGF23 processing in fibrous dysplasia

  2012cited by this paper
• McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia

  2012cited by this paper
• McCune-Albright syndrome

  2012cited by this paper
• NHERF-1 and the regulation of renal phosphate reabsoption: a tale of three hormones.

  2012cited by this paper
• Circulating αKlotho influences phosphate handling by controlling FGF23 production.

  2012cited by this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012cited by this paper
• A Phex mutation in a murine model of X‐linked hypophosphatemia alters phosphate responsiveness of bone cells

  2012cited by this paper
• Fibroblast Growth Factor-23-mediated Inhibition of Renal Phosphate Transport in Mice Requires Sodium-Hydrogen Exchanger Regulatory Factor-1 (NHERF-1) and Synergizes with Parathyroid Hormone*

  2011cited by this paper
• Tumor-induced osteomalacia.

  2011cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• A Systematic Study of Site-specific GalNAc-type O-Glycosylation Modulating Proprotein Convertase Processing*

  2011cited by this paper
• Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

  2011cited by this paper
• Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

  2011cited by this paper
• Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation

  2009cited by this paper
• Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site.

  2009cited by this paper
• Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia.

  2009cited by this paper
• Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis.

  2009cited by this paper
• Age‐Dependent Demise of GNAS‐Mutated Skeletal Stem Cells and “Normalization” of Fibrous Dysplasia of Bone

  2008cited by this paper
• A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidism

  2008cited by this paper
• A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

  2007cited by this paper
• Onset, Progression, and Plateau of Skeletal Lesions in Fibrous Dysplasia and the Relationship to Functional Outcome

  2007cited by this paper
• A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

  2007cited by this paper
• Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

  2007cited by this paper
• The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays

  2007cited by this paper
• Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions

  2007cited by this paper
• Klotho converts canonical FGF receptor into a specific receptor for FGF23

  2006cited by this paper
• Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*

  2006cited by this paper
• Fibrous Dysplasia as a Stem Cell Disease

  2006cited by this paper
• Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism

  2006cited by this paper
• G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome.

  2006cited by this paper
• Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.

  2006cited by this paper
• Gsα Mutations in Fibrous Dysplasia and McCune‐Albright Syndrome

  2006cited by this paper
• Hyperostosis–Hyperphosphatemia Syndrome: A Congenital Disorder of O‐Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23

  2006cited by this paper
• Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis

  2006cited by this paper
• Fibroblast Growth Factor‐23 Is Regulated by 1α,25‐Dihydroxyvitamin D

  2005cited by this paper
• An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

  2005cited by this paper
• Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

  2005cited by this paper
• Post‐translational Modification of Fibroblast Growth Factor 23

  2005cited by this paper
• Tumor-induced osteomalacia.

  2005cited by this paper
• Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.

  2005cited by this paper
• FGF-23 is elevated by chronic hyperphosphatemia.

  2004cited by this paper
• Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis

  2004cited by this paper
• An Instrument to Measure Skeletal Burden and Predict Functional Outcome in Fibrous Dysplasia of Bone

  2004cited by this paper
• Bone as a source of FGF23: regulation by phosphate?

  2004cited by this paper
• Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

  2004cited by this paper
• Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

  2004cited by this paper
• Osteomalacic and Hyperparathyroid Changes in Fibrous Dysplasia Of Bone: Core Biopsy Studies and Clinical Correlations

  2003cited by this paper
• FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

  2003cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

  2003cited by this paper
• Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

  2003cited by this paper
• Fracture Incidence in Polyostotic Fibrous Dysplasia and the McCune‐Albright Syndrome

  2003cited by this paper
• Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.

  2002cited by this paper
• The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.

  2001cited by this paper
• Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

  2001cited by this paper
• The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting

  2001cited by this paper
• Renal Phosphate Wasting in Fibrous Dysplasia of Bone Is Part of a Generalized Renal Tubular Dysfunction Similar to That Seen in Tumor‐Induced Osteomalacia

  2001cited by this paper
• Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

  2000cited by this paper
• Mutations of the GNAS1 Gene, Stromal Cell Dysfunction, and Osteomalacic Changes in Non–McCune–Albright Fibrous Dysplasia of Bone

  2000cited by this paper
• Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

  2000cited by this paper
• The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks.

  1999cited by this paper
• The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gsα gene: site‐specific patterns and recurrent histological hallmarks

  1999cited by this paper
• Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.

  1997cited by this paper
• Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function.

  1994cited by this paper
• Rapid GDP release from Gsα in patients with gain and loss of endocrine function

  1994cited by this paper
• Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.

  1992cited by this paper
• Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

  1991cited by this paper
• GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours

  1989cited by this paper
• The McCune‐Albright syndrome: a lethal gene surviving by mosaicism

  1986cited by this paper
• Hypophosphataemic osteomalacia in fibrous dysplasia.

  1976cited by this paper
• [Rickets following bone tumor].

  1959cited by this paper
• POLYOSTOTIC FIBROUS DYSPLASIA

  1938cited by this paper
• Syndrome Characterized by Osteitis Fibrosa Disseminata, Areas of Pigmentation and Endocrine Dysfunction, with Precocious Puberty in Females

  1937cited by this paper
• SOCIETY FOR PEDIATRIC RESEARCH

  1933cited by this paper

• Burosumab treatment of a child with McCune–Albright syndrome/polyostotic fibrous dysplasia: challenges and benefits

  2025cites this paper
• Burosumab treatment for FGF23-related hypophosphatemia in a two-year-old girl with McCune-Albright syndrome

  2025cites this paper
• Skeletal and endocrine manifestations of McCune-Albright syndrome in patients with fibrous dysplasia.

  2025cites this paper
• Fibrous dysplasia/McCune-Albright syndrome: pathogenesis, clinical description and management

  2025cites this paper
• Improvement of Fibrous Dysplasia After Burosumab Therapy in a Pediatric Patient with McCune-Albright Syndrome: A Case Report.

  2024cites this paper
• Iron Deficiency and Renal Phosphate Handling: The Role of Maximal Tubular Reabsorption of Phosphate Normalized to Glomerular Filtration Rate (TmP/GFR) in Proximal Tubular Dysfunction

  2024cites this paper
• Monostotic fibrous dysplasia of jaw bones: a case series

  2024cites this paper
• Inherited fibroblast growth factor 23 excess.

  2023cites this paper
• Fibrous dysplasia: a current concepts review

  2023cites this paper
• PTHrP Modulates the Proliferation and Osteogenic Differentiation of Craniofacial Fibrous Dysplasia-Derived BMSCs

  2023cites this paper
• RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia.

  2021cites this paper
• New technologies in oral radiology as a diagnostic aid for monostotic fibrous dysplasia: a review

  2021cites this paper
• Burosumab treatment for fibrous dysplasia.

  2021cites this paper
• Approach to patients with hypophosphataemia.

  2020cites this paper
• Genetics of Mineral Disorders

  2020cites this paper
• Hypophosphataemic Rickets: Similar Phenotype of Different Diseases

  2020cites this paper
• Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium

  2020cites this paper
• Inherited Disorders of Calcium, Phosphate, and Magnesium

  2019cites this paper
• McCune–Albright Syndrome

  2019cites this paper
• Fibrous dysplasia/McCune-Albright syndrome: a rare, mosaic disease of Gαs activation.

  2019cites this paper
• Overview of Genetically Determined Diseases/Multiple Endocrine Neoplasia Syndromes Predisposing to Endocrine Tumors.

  2019cites this paper
• When Low Bone Mineral Density and Fractures Is Not Osteoporosis

  2019cites this paper
• Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the femur: A case report

  2019cites this paper
• Bone Tumors

  2019cites this paper
• Fibrous dysplasia imitating malignancy.

  2018cites this paper
• Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia

  2018cites this paper
• Tumor-induced osteomalacia caused by a massive phosphaturic mesenchymal tumor of the acetabulum: A case report

  2018cites this paper
• Fibrous dysplasia of bone: craniofacial and dental implications.

  2017cites this paper
• Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.

  2017cites this paper
• Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT.

  2017cites this paper
• Fibrous dysplasia. Clinical review and therapeutic management.

  2016cites this paper
• Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment

  2016cites this paper
• Pseudotumors of bone and bone lesions mimicking tumours

  2016cites this paper
• Fibrous dysplasia. Clinical review and therapeutic management

  2016cites this paper
• Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives

  2016cites this paper
• Bone Disease in the Common Marmoset

  2015cites this paper
• FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis

  2014cites this paper